Intermittent androgen blockade should be regarded as standard therapy in prostate cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

24 citing papers in PubMed.

1. Steroid hormones: risk and resilience in women's Alzheimer disease.Frontiers in aging neuroscience · 2023
   Review
2. Testosterone therapy and prostate cancer.Translational andrology and urology · 2016
   Review
3. Testosterone Therapy Among Prostate Cancer Survivors.Sexual medicine reviews · 2016
   Review
4. Androgen receptor regulates SRC expression through microRNA-203.Oncotarget · 2016
   Article
5. Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase.Oncotarget · 2015
   Article
6. Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, CyclinA, and Skp2.PloS one · 2014
   Article
7. Tumor metastasis: moving new biological insights into the clinic.Nature medicine · 2013
   Review
8. Drug rechallenge and treatment beyond progression--implications for drug resistance.Nature reviews. Clinical oncology · 2013
   Review
9. Caffeic Acid phenethyl ester as a potential treatment for advanced prostate cancer targeting akt signaling.International journal of molecular sciences · 2013
   Article
10. Dentatin Induces Apoptosis in Prostate Cancer Cells via Bcl-2, Bcl-xL, Survivin Downregulation, Caspase-9, -3/7 Activation, and NF-κB Inhibition.Evidence-based complementary and alternative medicine : eCAM · 2012
    Article
11. Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.Cancer science · 2011
    Article
12. Type I Collagen Synthesis Marker Procollagen I N-Terminal Peptide (PINP) in Prostate Cancer Patients Undergoing Intermittent Androgen Suppression.Cancers · 2011
    Article
13. Stochastic dynamics of leukemic cells under an intermittent targeted therapy.Theory in biosciences = Theorie in den Biowissenschaften · 2011
    Article
14. Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer.Journal of biomedical science · 2011
    Review
15. Pharmacotherapeutic management of locally advanced prostate cancer: current status.Drugs · 2011
    Review
16. Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2010
    Article
17. An update on androgen deprivation therapy for prostate cancer.Endocrine-related cancer · 2010
    Review
18. Metronomic chemotherapy: new rationale for new directions.Nature reviews. Clinical oncology · 2010
    Review
19. Measurement of bone turnover in prostate cancer patients receiving intermittent androgen suppression therapy.Open access journal of urology · 2010
    Article
20. Intermittent androgen deprivation therapy: redefining the standard of care?Reviews in urology · 2010
    Article

Corrections and comments

• Commented on by
  Response to 'Intermittent androgen blockade should be regarded as standard therapy in prostate cancer'.2009

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as